-
A combination of disappointing data and urging by a panel of physicians against blockbuster cholesterol drug Vytorin dented two pharma giants, as the annual meeting of the American College of Cardiology (Washington) got under way in Chicago.
-
Clot-busting drug therapy, when administered to patients after a stroke, appears to work more effectively if the patient already has been on an anti-platelet medication. However, this might also increase the risk for bleeding within the brain.
-
One of the ongoing battles pitting "minimally invasive" against open surgical approaches is in clearing the carotid arteries to avoid stroke, or as therapy following stroke.
-
The Centers for Medicare & Medicaid have been especially busy in the cardiovascular sector the past few weeks, resisting coverage, or added coverage, in some areas, approving broader coverage in at least one sector.
-
CardioMind (Sunnyvale, California), an under-the-radar developer of coronary stents, has its eye on a specific, underserved sector of the drug-eluting stent (DES) sector: the worldwide market for vessel "scaffold" devices.
-
A study assessing Boston Scientific's (Natick, Massachusetts) EZ FilterWire to catch bits of plaque and blood clot that break loose during percutaneous coronary intervention (PCI) in patients with acute coronary syndrome has been discontinued after it failed to show that it can reduce rates of major cardiovascular complications.
-
eResearchTechnology; nSpire Health, Advanced Cell Technology; Chandler Regional Medical Center; Mercy Gilbert Medical Center; Catholic Healthcare West; Alliant Healthcare Products; Premier Purchasing Partners; Angiotech Pharmaceuticals; Rex Medical; Cardiac Science; Misys Healthcare; Cardinal Health; GE Healthcare; Global Research Services; CardioDynamics; Piedmont Heart Institute; Cardiology of Georgia; Piedmont Healthcare
-
Results from a six-month economic analysis comparing the cost of off-pump, "beating heart" coronary artery bypass graft (CABG) procedures with the cost of traditional on-pump CABG surgery showed that beating-heart CABG saved $1,684 per procedure compared to traditional bypass surgery.
-
Charles Maroney has been president/CEO, since February 2006, of CardioMind (Sunnyvale, California), a development-stage company focused on a small-diameter stent delivery platform with applications in treating coronary, neuro and peripheral artery disease. This is currently a $5 billion-plus worldwide market.
-
The implantable cardiac defibrillator (ICD) market may be poised to rebound from the black eye it has suffered following recalls and recent lead malfunctions, based on news from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) trial - intended to establish that patients with mild heart failure may benefit from cardiac resynchronization therapy (CRT).
